Left Bundle Branch Pacing on Outcomes and Ventricular Remodeling in Biventricular CRT Nonresponders

Recruiting · NCT05760924 · Interventional (participants receive a specific treatment) · Lead sponsor: Tomsk National Research Medical Center of the Russian Academy of Sciences

View the official record on ClinicalTrials.gov →

Heart Failure

Interventions studied

CRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right Ventricular PacingCRT-D or CRT-D Leads Replacement with New Lead Implantation to Left Bundle Branch and Inactivation of Conventional Right and Left Ventricular PacingCardiac Resynchronization Therapy Devices with Defibrillator Function (CRT-D) or CRT-D Leads Replacement

What this trial is about

Heart failure (HF) is the most common nosology encountered in clinical practice. Its incidence and prevalence increase exponentially with increasing age and it is associated with the increased mortality, more frequent hospitalization and decreased quality of life. An initial approach to the treatment of HF patients with reduced left ventricular (LV) systolic function and left bundle branch block (LBBB) was implantation of device for cardiac resynchronization therapy using biventricular pacing. This has resulted in long-term clinical benefits such as improved quality of life, increased functional capacity, reduced HF hospitalizations and overall mortality. However, conventional cardiac resynchronization therapy (CRT) is effective in only 70% of patients. And the remaining 30% of patients are non-responders to conventional CRT. Cardiac conduction system pacing is currently a promising technique for these patients. Particularly, His bundle pacing (HBP) has been developed to achieve the same results. According to other studies HBP has shown greater improvement in hemodynamic parameters comparing with conventional biventricular CRT. But, nevertheless, there are significant clinical troubles with HBP, especially high pacing threshold. In this regard, in 2017, the left bundle branch pacing (LBBP) was developed, which demonstrated clinical advantages compared to conventional biventricular CRT. Also, since 2019, left bundle branch pacing-optimized CRT (LBBPO CRT) has been used in clinical practice. These methods have become an alternative to HBP due to the stimulation of LBB outside the blocking site, a stable pacing threshold and a narrow QRS complex duration on electrocardiogram. A series of case reports and observational studies have demonstrated the efficacy and safety of LBBP and LBBPO CRT in patients with CRT indications. However, it is not enough data about impact of CRT with LBBP and combined CRT with LBBP and LV pacing on myocardial remodeling, reducing mortality and complications. According to our hypothesis, CRT with LBBP and combined CRT with LBBP and LV pacing compared with conventional biventricular pacing will significantly improve the clinical outcomes and reverse myocardial remodeling in patients who are non-responders to biventricular CRT with HF, reduced LV ejection fraction and with indications to CRT devices with defibrillator function (CRT-D) or one of the CRT-D leads replacement.

Who can take part

Age range

18 Years to 80 Years

Sex

All (male and female)

Healthy volunteers

No - a diagnosis or condition is required

Phase

Not applicable (e.g. observational or device study)

Study type

Interventional (participants receive a specific treatment)

Inclusion criteria

The patient is willing and able to comply with the protocol and has provided written informed consent;
Male or female patients aged 18 to 80 years;
Patients with ischemic or non-ischemic cardiomyopathy;
Symptomatic HF for at least 3 months prior to enrollment in the study;
New York Heart Association (NYHA) functional class HF ≥ II;
Patients who are non-responders to biventricular CRT with HF, reduced LVEF and CRT-D replacement or one of the CRT-D leads replacement indications (without LVEF increase ≥ 5% and/or without a left ventricle end-systolic volume decrease ≥ 15% after CRT-D implantation at least 1 year old);
Optimal HF medical therapy.

Exclusion criteria

Coronary artery (CA) bypass grafting, balloon dilatation or CA stenting within 3 months prior to enrollment;
Acute myocardial infarction within 3 months prior to enrollment;
Acute coronary syndrome;
Patients with planned cardiovascular intervention (CA bypass grafting, balloon dilatation or CA stenting);
Patients listed for heart transplant;
Patients with implanted cardiac assist device;
Acute myocarditis;
Infiltrative myocardial disease;
Hypertrophic cardiomyopathy;
Severe primary stenosis or regurgitation of the mitral, tricuspid and aortic valves;
Woman currently pregnant or breastfeeding or not using reliable contraceptive measures during fertility age;
Mental or physical inability to participate in the study;
Patients unable or unwilling to cooperate within the study protocol;
Patients with rheumatic heart disease;
Mechanic tricuspid valve patients;
Patients with any serious medical condition that could interfere with this study;
Enrollment in another investigational drug or device study;
Patients not available for follow-up;
Patients with severe chronic kidney disease (estimated glomerular filtration rate ˂ 30 ml/min/1.73 m2);
Life expectancy ≤ 12 months;
Participation in another telemonitoring concept.

Where it is running

1 location listed.

Cardiology Research Institute, Tomsk National Research Medical Center, Russian Academy of Sciences - Tomsk, Russia

Read the full protocol, contacts and eligibility on ClinicalTrials.gov →